Tetrapeptide analog of TRH
AssigneeMerck & Co., Inc.
InventorsDaniel F. Veber, Ruth F. Nutt, Ralph F. Hirschmann
Life of this patent
Estimating the term…
Abstract
A novel tetrapeptide L-2-ketopiperidine-6-carbonyl-L-histidyl-L-thiazolidine-4-carbonyl-.beta.- alanin-amide, (L-Kpc-L-His-L-Tca-.beta.-ala-NH.sub.2), is a stimulant of the central nervous system. It is preparable by standard peptide synthetic procedures.
Claims5
A process for the preparation of the compound of formula:
- L-Kpc-L-His-L-Tca-.beta.-Ala-NH.sub.2
- or a pharmaceutically acceptable salt thereof, which comprises the formation of a peptide bond between:
- 1. L-Kpc-OH and L-His-L-Tca-.beta.-Ala-NH.sub.2 ;
- 2. l-kpc-L-His-OH and L-Tca-.beta.-Ala-NH.sub.2 ;
- 3. l-kpc-L-His-L-Tca-OH and .beta.-ala-NH.sub.2 ;
- or
- 4. L-Kcp-His-L-Tca-.beta.-Ala-OH and NH.sub.3.
The compound of formula:
- L-Kpc-L-His-L-Tca-.beta.-Ala-NH.sub.2
- or a pharmaceutically acceptable salt thereof.
A method of treating central nervous system depression which comprises administration to a patient in need of such treatment an effective amount of a compound of formula:
- L-Kpc-L-His-L-Tca-.beta.-Ala-NH.sub.2
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a pharmaceutical carrier and an effective amount of a compound of formula:
- L-Kpc-L-His-L-Tca-.beta.-Ala-NH.sub.2
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.